BloggingStocks has a new home! Daily Finance.
Click here to visit the new home of BloggingStocks!
What Happened When Alex Kenjeev Paid His Student Loan in Cash
America's 10 Highest-Paid CEOs of 2011 (and How They Earned It)cancer stocks posts
FeedThis post is part of a special report, Top Picks for 2010, the 27th annual survey in which TheStockAdvisors.com asks the nation's leading advisors for their single favorite stock for the new year. See all 80 stocks listed here.
"Our top stock pick for 2010 is ImmunoGen (IMGN)," says biotech specialist John McCamant.
In his The Medical Technology Stock Letter, he explains, "The company's potent cancer-cell killing antibodies were developed for targeted delivery to tumor cells."
"Some sectors tend to do better than others in tough times; biotechnology often surprises investors in good times and bad," suggests Brandon Clay.
In his Invest with an Edge advisory service, the growth stock advisor looks to Celgene Corporation (NASDAQ: CELG), a player in developing cancer treatments. Here's his review.
"This sometimes-perilous market niche can make or break a portfolio depending on several factors: drug pipeline, continued investment, market factors, and government approvals.
"However, despite the risks, there are times when we believe that individual biotech stocks make sense -- such as our latest recommendation for Celgene.
Continue reading Celgene (CELG): Cancer progress boosts biotech
Find out why more people track their portfolios on AOL Money & Finance then anywhere else.
Goldman Earnings Sink After Buffett Dividend
Johnson & Johnson's Income Falls 23%
Burberry Shares Leap on Sales Update